

# AlÃ- Duarte-GarcÃ-a

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8018663/publications.pdf>

Version: 2024-02-01

52  
papers

1,641  
citations

393982

19  
h-index

315357

38  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Festina lente": hydroxychloroquine, COVID-19 and the role of the rheumatologist" by Graef et al" by Lo et al. Annals of the Rheumatic Diseases, 2022, 81, e164-e164.	0.5	2
2	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	1.0	9
3	Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study. Rheumatology, 2022, 61, 2424-2431.	0.9	12
4	Risk of hydroxychloroquine retinopathy in the community. Rheumatology, 2022, 61, 3172-3179.	0.9	5
5	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Arthritis and Rheumatology, 2022, 74, 766-775.	2.9	117
6	Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Care and Research, 2022, 74, 728-732.	1.5	7
7	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Frontiers in Immunology, 2022, 13, 834981.	2.2	19
8	Industry involvement in rheumatology consensus-based recommendations: a systematic review. Lancet Rheumatology, The, 2022, 4, e145-e152.	2.2	0
9	Time to transition from psoriasis to psoriatic arthritis: A population-based study. Seminars in Arthritis and Rheumatism, 2022, 52, 151949.	1.6	6
10	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings, 2022, 97, 250-260.	1.4	10
11	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	2.2	30
12	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases, 2022, 81, 861-867.	0.5	35
13	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.5	49
14	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. Rheumatology, 2022, 61, 4962-4974.	0.9	3
15	Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Annals of the Rheumatic Diseases, 2022, 81, 1260-1266.	0.5	23
16	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	2.9	52
17	Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus. Canadian Journal of Neurological Sciences, 2021, 48, 415-416.	0.3	2
18	28-Year-Old Woman With Chronic Kidney Disease, Fatigue, and Polyarthralgias. Mayo Clinic Proceedings, 2021, 96, 231-236.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1410-1416.	1.0	25
20	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101659.	1.4	9
21	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
22	28-Year-Old Man With Recurrent Vertigo, Syncope, and Progressive Memory Impairment. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1309-1314.	1.4	0
23	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1878-1885.	2.9	25
24	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1767-1768.	2.9	0
25	Industry Payments to Practicing US Rheumatologists, 2014-2019. <i>Arthritis and Rheumatology</i> , 2021, 73, 2138-2144.	2.9	22
26	Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	0
27	75-Year-Old Man With Fever and Malaise. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2905-2910.	1.4	0
28	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
29	Epidemiology of Antiphospholipid Syndrome in the General Population. <i>Current Rheumatology Reports</i> , 2021, 23, 85.	2.1	49
30	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e21-e21.	0.5	15
31	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	2.0	177
32	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
33	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102688.	2.5	17
34	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 47-71.	1.5	11
35	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	0.8	80
36	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 2164-2165.	2.9	0

#	ARTICLE	IF	CITATIONS
37	Reply. Arthritis and Rheumatology, 2020, 72, 1776-1776.	2.9	0
38	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review of Clinical Immunology, 2020, 16, 659-666.	1.3	57
39	Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. Arthritis and Rheumatology, 2020, 72, 733-749.	2.9	51
40	Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 1348-1356.	1.6	13
41	Treatment of thrombotic antiphospholipid syndrome in adults and children. Current Opinion in Rheumatology, 2020, 32, 215-227.	2.0	8
42	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. Annals of the Rheumatic Diseases, 2020, 79, 734-736.	0.5	35
43	Reply. Arthritis and Rheumatology, 2019, 71, 1769-1770.	2.9	0
44	Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines. ACR Open Rheumatology, 2019, 1, 188-193.	0.9	7
45	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. Arthritis and Rheumatology, 2019, 71, 1545-1552.	2.9	172
46	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	1.0	36
47	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. Annals of Internal Medicine, 2019, 171, 602.	2.0	3
48	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. Annals of Internal Medicine, 2019, 170, 791.	2.0	9
49	The Evidence Basis for the American College of Rheumatology Practice Guidelines. JAMA Internal Medicine, 2018, 178, 146.	2.6	33
50	Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction. PLoS ONE, 2018, 13, e0196487.	1.1	21
51	Antiphospholipid Syndrome. Journal of the American College of Cardiology, 2017, 69, 2317-2330.	1.2	109
52	Predictors of incident proteinuria among patients with SLE. Lupus Science and Medicine, 2017, 4, e000200.	1.1	19